AZNCF News and Press, AstraZeneca Plc From 09/17/23

2023-09-17 12:00:54 ET The impact of COVID, flu, and RSV on U.S. and U.K. hospitals is expected to be lower this winter compared to last, as there won't be a significant overlap between peak outbreaks of infections, the London-based data analytics firm Airfinity said in a recent report. ...

2023-09-16 08:26:36 ET Summary The sector as a whole is overvalued by about 15% relative to 11-year averages. Healthcare providers and pharmaceuticals/biotechnology look fairly valued, whereas healthcare equipment is the less attractive subsector. IXJ: a global alternative to ...

2023-09-15 13:02:18 ET Summary Currently, the S&P 500 and many sectors are outperforming the healthcare sector, presenting an opportunity to explore assets within this sector during the current period of apathy towards it. AstraZeneca's revenue was $11.42 billion in the second...

2023-09-03 03:45:00 ET Summary Shanghai GenFleet Technologies partners with Verastem in a deal worth up to $625.5 million for three preclinical small-molecule candidates for RAS pathway-driven cancers. Shanghai Kangpu Biopharmaceuticals raises $13.8 million in a B funding round to...

2023-08-24 02:20:26 ET Summary Bristol-Myers has a strong history of investment outperformance during equity bear markets and recessions. The company is uniquely undervalued, with a low 8x P/E and nearly 4% cash dividend yield. After a weak first half of 2023, shares may rebou...

2023-08-22 07:30:00 ET Summary The annual economic symposium at Jackson Hole is eagerly awaited for insights into the Fed's next policy actions. Powell will likely continue to be hawkish given the still-elevated inflation and strong activity data. But even beyond the Fed, insights...

2023-08-14 05:45:30 ET Summary Coya Therapeutics is developing Treg-enhancing therapeutics to target diseases driven by inflammation, including in the central nervous system, including ALS. Coya Therapeutics' ALS drug could be approved based on pivotal phase 2 results and could po...

2023-08-13 07:00:00 ET Summary BeiGene and Bristol-Myers Squibb have completed the breakup of their partnership, with BeiGene regaining shares worth $340 million. Gracell Biotechnologies raised $100 million in a private placement to support the development of its CAR-T therapies. ...

2023-08-11 17:59:00 ET Summary Hutchmed (China) Limited, a Chinese biopharma company, has experienced fluctuations in its stock price but has potential for improvement. The company acts as a liaison between the healthcare systems of China and the U.S., working to get its products ...

2023-08-10 11:01:31 ET Summary Organon & Co. posted its Q2 2023 earnings on 8th August. The Merck spinouts' 3 main divisions are Women's Health, Biosimilars, and Established Brands. Total revenues were $1.6bn - up 4% ex-FX fluctuations - and diluted EPS was $0.95 - both ou...